Scientists found that patients with raised tumor-infiltrating CD8+ T cells and TCF-1+stem cell-like CD8+ T cells at the time of surgery tend to experienced robust immune responses and improved survival after subsequent immunotherapy (51). Here, CD8A is linked to neoplasm.